Document Detail

Bisphosphonates or prostacyclin in the treatment of bone-marrow oedema syndrome of the knee and foot.
MedLine Citation:
PMID:  23143557     Owner:  NLM     Status:  Publisher    
Bone-marrow oedema (BME) represents a reversible but mostly painful increase in interstitial fluid. The exact pathogenetic processes still remain unknown. Treatment options are mainly symptomatic with core decompression as golden standard leading to immediate pain relieve. Recently, it has been shown that intravenous prostacyclin and bisphosphonates are useful in achieving a reduction in BME with a considerable improvement in the accompanying symptoms. We compared the outcome of both intravenously applied prostacyclin (Ilomedin(®), 10 patients) and bisphosphonate (Bondronat(®), 10 patients) in treatment of BME of the knee and foot. We could find a significant improvement of WOMAC score, SF-36 score and VAS 3 months and 1 year after therapeutic intervention in both the prostacyclin and the bisphosphonate group. Concerning the MRI scans in both groups, we found a distinct reduction of BME in 47 % and a complete regression in 40 %. Comparing both groups, the improvement of the scores was greater in the prostacyclin group than in the bisphosphonate group; the difference, however, was not significant. Intravenous bisphosphonates as well as prostacyclin are of efficient therapeutic benefit in treatment of BME with a quicker and greater effect of prostacyclin.
Clemens Baier; Jens Schaumburger; Jürgen Götz; Guido Heers; Thorsten Schmidt; Joachim Grifka; Johannes Beckmann
Related Documents :
24026627 - Prostanoid therapy for pulmonary arterial hypertension: a meta-analysis of survival out...
23380557 - A "christmas tree" band for the treatment of arteriovenous dialysis access-related stea...
24368097 - Treatment of corneal ulcers with platelet rich plasma.
23811957 - Periprocedural aspects in mechanical recanalization for acute stroke: data from the end...
11397887 - Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels...
25101227 - Adherence to an overweight and obesity treatment: how to motivate a patient?
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-10
Journal Detail:
Title:  Rheumatology international     Volume:  -     ISSN:  1437-160X     ISO Abbreviation:  Rheumatol. Int.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8206885     Medline TA:  Rheumatol Int     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Orthopaedic Surgery, University Hospital of Regensburg, Bad Abbach, Germany,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Elevated serum levels of high mobility group box protein 1 (HMGB1) in patients with ankylosing spond...
Next Document:  Estradiol regulates miR-135b and mismatch repair gene expressions via estrogen receptor-? in colorec...